Our last post highlighted the end-of-the-month release of the long-awaited generic version of Lipitor, the most popular cholesterol-lowering drug in America. Brand-name Lipitor, manufactured by drug giant Pfizer, has been one of the key contributors to American’s high drug bills for the past 15 years. A generic version will mean massive savings for some and basic affordability for many.
Last week, however, the New York Times shared that Pfizer (unsurprisingly) wants to block access to that affordable generic. Pfizer is going to offer “large discounts for benefit managers that block the use of generic versions of Lipitor” – “When patients submit a prescription for a generic version of Lipitor, they are to be given Lipitor instead.” So, those covered by the benefit managers who accept the discount will end up paying the same high co-pay, despite the availability of a lower priced drug!
These tactics by the largest drug manufacturer to keep drug prices higher are disappointing but not surprising. After all, in addition to lobbying the U.S. government to prevent safe personal drug importation, it funds programs to scare Americans away from buying its own medication at a lower price from Canada and other countries.
Pfizer’s latest move seems to only affect Americans with health insurance who, under the Pfizer/benefit manager deal, would pay $25 monthly co-pays (instead of $10 per month) – that’s $75 for a three month supply. That’s a stark contrast to Americans without health insurance who can pay $535.00 at a local CVS in New York City. By comparing prices of verified online pharmacies at PharmacyChecker.com, the uninsured may at least knock their monthly brand name Lipitor costs to $85.70.
Fortunately, due to the economics of generic drug competition, generic Lipitor prices will eventually offer great savings to the uninsured and we’ll be keeping you updated as those new products come to market.
Tagged with: brand-name, Cholesterol, co-pays, CVS, generic drugs, health insurance, insured, Lipitor, New York City, New York Times, PBM, Pfizer, pharmacy benefit managers, pharmacychecker.com, uninsured, United States
As reported in the The Inquisitr, due to generic competition, Lipitor prices are going to plummet in the near future, a relief not only to American patients but to U.S. doctors who often find their patients not taking their cholesterol medication due to cost. In discussing his patients, Dr. Thomas Haffey stated in the article:
They often make tough decisions about whether they eat or whether they take the medicines… Any time you can reduce the costs of quality health care, we certainly are happy and encouraged about that.
High drug prices in the United States lead to 10s of millions of Americans not taking needed medication each year. The end of Pfizer’s patent on Lipitor means that Americans will now be able to more easily afford Atorvastatin – the generic name for Lipitor – in local U.S. pharmacies. As of the end of this month, according The Missourian, a three-month supply of generic Lipitor will cost $30. And the Inquisitr article suggests that within six months generic Lipitor will be priced at $5 for a one-month supply.
To maintain market share, Pfizer, the manufacturer of Lipitor, may come up with some competitive sales strategies. For instance, Pfizer may cut costs for insured Americans to only $4/month co-pays. Pfizer is also pushing to market an over-the-counter version of Lipitor, however it is not yet approved for sale.
According to our research, U.S. prices for a 90-day supply of Lipitor 20mg at a New York City CVS costs $535.99, compared to $85.70 at the lowest cost online pharmacy approved by PharmacyChecker.com – a savings of 84%. So if you want the brand name drug you may be better off with low-cost online pharmacies. But, come the end of November, the best prices for generic Lipitor will soon be available in the good old USA.
Tagged with: Atorvastatin, bricks and mortar, Cholesterol, co-pay, cost, coupon, CVS, generic, Lipitor, over-the-counter, patent, Pfizer, pharmacy, pharmacy checker.com, The Inquisitr, The Missourian, United States
Generic prescriptions are on the rise, as doctors are prescribing them, and pharmacies are filling them, now more than ever. We recently wrote that the percentage of generic scripts being dispensed rose to 78% last year. But the popularity for generics – attributed to the significantly lower price tag compared to brand name drugs – is expected to take on a whole new meaning, as the patents for some blockbuster brand name drugs expire this year; this is also known as the “Patent Cliff”.
The biggest prize, Pfizer’s Lipitor (for Cholesterol), the number one selling drug in the U.S., goes generic later this year (November 2011); and Plavix (a blood thinner) and Actos (for Diabetes) will follow (May 2012 and August 2012, respectively). As patents run out, these and other popular prescription drugs will be far more affordable in the U.S., since generic drug prices tend to be lower here than in other countries. (more…)
Tagged with: Actos, blood thinner, brand name drugs, Canada, Celebrex, Cholesterol, consumer guide, Costco.com, diabetes, generic prescriptions, Lipitor, Patent Cliff, Pfizer, Plavix, Seroquel, Simvastatin, U.S. pharmacies, United States, Zocor